|
|
|
Volumn 26, Issue 2, 1999, Pages 217-226
|
|
Drug development in prostate cancer
a
a
a
K6/550 CSC
*
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
DOXERCALCIFEROL;
FLAVONE DERIVATIVE;
FLAVOPIRIDOL;
PERILLYL ALCOHOL;
PRINOMASTAT;
TERPENE DERIVATIVE;
VITAMIN D DERIVATIVE;
DRUG MECHANISM;
DRUG RESEARCH;
DRUG SCREENING;
DRUG STRUCTURE;
HUMAN;
MALE;
PRIORITY JOURNAL;
PROSTATE CANCER;
REVIEW;
UNITED STATES;
ANGIOGENESIS INHIBITORS;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC AGENTS, HORMONAL;
APOPTOSIS;
CELL CYCLE;
CELL DIFFERENTIATION;
CLINICAL TRIALS;
CYCLIN-DEPENDENT KINASES;
DRUG RESISTANCE, NEOPLASM;
FLAVONOIDS;
HUMANS;
MALE;
MONOTERPENES;
NEOPLASM METASTASIS;
NEOVASCULARIZATION, PATHOLOGIC;
PIPERIDINES;
PROSTATIC NEOPLASMS;
SIGNAL TRANSDUCTION;
SURVIVAL RATE;
TERPENES;
VITAMIN D;
|
|
EID: 0032931487
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (24)
|
|
References (46)
|
